Study provides valuable insights into the evolutionary dynamics of hepatitis E virus

A combination therapy with multiple drugs is more effective than just one active compound. To begin with, at least.

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK – Biotech Investments

Issuer: CureVac / Key word(s): Study 01.08.2023 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Dosing of

August 2, 2023

Why Authentic Engagement Still Matters in Healthcare Marketin

Emanuel Engelmayer, Client Success Manager at G-Med As AI continues to revolutionize healthcare marketing by automating tasks and improving efficiencies, one truth remains steadfast: the power

February 10, 2025

Allergies linked to heightened risk of long COVID, new review suggests

Systematic review indicates that pre-existing allergic conditions like asthma and allergic rhinitis may be linked to an increased risk of developing long COVID. Despite some

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.